Scarica l'app Stockscreener
0.99
7.48%
-0.08
Dopo l'orario di chiusura:
1.02
0.03
+3.03%
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Coherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR Details - Quiver Quantitative
Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. - stocktitan.net
Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets - Yahoo Finance
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets - Yahoo Finance
Coherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR Details - Quiver Quantitative
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets - The Manila Times
Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - ad-hoc-news.de
CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn
Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance
Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView
Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com South Africa
CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com Nigeria
Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com Canada
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com UK
Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com
Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - Yahoo Finance
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales - Quiver Quantitative
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - MarketBeat
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Post-Earnings Moves - dars.gov.et
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27High Conviction Picks - dars.gov.et
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Algorithmic Stock Picks - dars.gov.et
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology : Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Canada
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):